This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of degenerative nerve diseases: A Synthesis of Findings from 96 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of degenerative nerve diseases: A Synthesis of Findings from 96 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Chronic hepatitis B (CHB) is a serious liver disease that can lead to cirrhosis and liver cancer. Various treatment combinations of peginterferon (PEG-IFN) and nucleos(t)ide analogues have been evaluated for CHB, but the optimal regimen remains unclear. 77

PEG-IFN has shown promise in treating CHB, particularly when combined with nucleotide analogues. 72 In patients with low viral loads, PEG-IFN plus nucleotide analogue therapy may lead to functional cure, marked by the loss of hepatitis B surface antigen (HBsAg) with or without the development of antibodies against HBsAg (anti-HBs). 72

However, treatment is not always recommended for patients with low viral loads, as there is ongoing debate about the necessity of treatment in such cases. 72 Further research is needed to determine the optimal prophylactic antiviral protocol for patients with lymphoma treated with rituximab-containing chemotherapies, as HBV reactivation poses a serious risk. 66

Treatment summary

Treatment for chronic hepatitis B may involve interferon monotherapy, nucleoside(t) analogue monotherapy, or combination therapy of interferon and nucleoside(t) analogues. 59 75 85 94

PEG-IFN, while effective on its own, can potentially achieve HBsAg loss when combined with nucleoside(t) analogues. 72 73 Lamivudine or other antiviral drugs are recommended for prophylaxis in lymphoma patients undergoing rituximab-containing chemotherapy. 66

Benefits and risks

Benefit Summary

Treatment for chronic hepatitis B can suppress liver inflammation and damage, thereby reducing the risk of developing cirrhosis and liver cancer. 52 68 Treatment can also lower viral load and improve liver function. 7 9 75

Risk Summary

Interferon can cause side effects such as fatigue, fever, muscle aches, and gastrointestinal problems. 8 10 94 23 While generally safe, nucleoside(t) analogues can lead to the emergence of drug-resistant viruses. 53

Comparison of studies

Commonalities between studies

Many studies highlight the effectiveness of interferon and nucleoside(t) analogues in treating chronic hepatitis B. 8 1 50 53 59 68

Differences between studies

There is variation across studies regarding interferon administration methods, duration of treatment, efficacy, and side effects. 8 10 94 23

Consistency and contradictions in results

While many studies support the efficacy of interferon and nucleoside(t) analogues in treating chronic hepatitis B, some studies report conflicting findings regarding interferon's effectiveness and side effects. 8 10 94 23

Considerations for real-world application

Tailoring treatment to each individual patient's condition is crucial when managing chronic hepatitis B. 67 Consult with a physician before starting treatment to fully understand the potential risks and benefits.

Limitations of current research

While treatment for chronic hepatitis B has significantly advanced in recent years, challenges remain. 53 59 68 For example, there is a lack of research evaluating the long-term efficacy and safety of treatments. 75 Furthermore, more research is needed to understand factors like genetics and immune status that may influence treatment outcomes. 49

Future research directions

Further research is essential for advancing chronic hepatitis B treatment. This includes studies evaluating long-term efficacy and safety, developing personalized treatments tailored to individual patients, and finding ways to prevent the emergence of drug-resistant viruses. 52 54 68

Conclusion

Chronic hepatitis B is a serious liver disease, but advancements in treatment options allow many patients to effectively manage their condition and live healthy lives. 64 95 If you are infected or suspect you may be infected with the hepatitis B virus, consulting a physician for appropriate testing and treatment is critical.

Treatment List

Interferon, nucleoside(t) analogues, PEG-interferon, lamivudine, entecavir, tenofovir, telbivudine, famciclovir, hepatitis B immunoglobulin (HBIg), chemotherapy, vaccine.


Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 96 papers
Positive Content
90
Neutral Content
3
Negative Content
3
Article Type
59
32
25
17
96

Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : German


Language : English


Language : German


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Chinese


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: LauGeorge K K, PiratvisuthTeerha, LuoKang Xian, MarcellinPatrick, ThongsawatSatawat, CooksleyGraham, GaneEdward, FriedMichael W, ChowWan Cheng, PaikSeung Woon, ChangWen Yu, BergThomas, FlisiakRobert, McCloudPhilip, PluckNigel,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: ChanHenry L Y, HeathcoteE Jenny, MarcellinPatrick, LaiChing-Lung, ChoMong, MoonYoung M, ChaoYou-Chen, MyersRobert P, MinukGerald Y, JeffersLennox, SievertWilliam, BzowejNatalie, HarbGeorge, KaiserRalf, QiaoXin-Jian, BrownNathaniel A,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Chinese


Language : English


Language : Chinese


Language : English


Language : English


Language : English


Language : English


Author: LokAnna S F, McMahonBrian J, BrownRobert S, WongJohn B, AhmedAhmed T, FarahWigdan, AlmasriJehad, AlahdabFares, BenkhadraKhalid, MouchliMohamed A, SinghSiddharth, MohamedEssa A, Abu DabrhAbd Moain, ProkopLarry J, WangZhen, MuradMohammad Hassan, MohammedKhaled


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: AhnSang Hoon, MarcellinPatrick, MaXiaoli, CaruntuFlorin A, TakWon Young, ElkhashabMagdy, ChuangWan-Long, TabakFehmi, MehtaRajiv, PetersenJörg, GuyerWilliam, JumpBelinda, ChanAlain, SubramanianMani, CransGerald, FungScott, ButiMaria, GaetaGiovanni B, HuiAric J, PapatheodoridisGeorge, FlisiakRobert, ChanHenry L Y


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.